Management of Gout PHARMACIST S LETTER / PRESCRIBER S LETTER

Background Gout is a painful inflammatory arthritis cause by precipitation of monosodium urate crystals. It is a condition that more commonly affects middle age and older adults. The management of gout includes treating acute attacks, urate-lowering therapy, and preventing recurrence of acute attacks. This document reviews the latest treatments of gout. Detail-Document #261102 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER November 2010 ~ Volume 26 ~ Number 261102 Management of Gout Management of Acute Gout Acute gout attack is characterized by sudden onset of severe debilitating pain with progressive worsening over the first 24 hours. Most attacks usually resolve within three to ten days. Generally joint rest for a few days helps resolve attacks and icing the affected site may reduce pain. Fast acting NSAIDs are generally the drugs of choice for the treatment of acute gout when there are no contraindications. 1 However, their use is limited in patients with renal insufficiency, risk factors for gastrointestinal (GI) bleeding, or comorbidities such as heart failure. The risk of side effects such as dyspepsia, hyperkalemia, and azotemia increase with advanced age. 2 In patients without renal insufficiency, GI bleeding risk, or other problematic comorbidities, NSAIDs should be started within 12 to 24 hours of acute attack for maximum benefit. 3 Start NSAIDs at the highest dose for two to three days, then decrease over approximately two weeks. 4 Continue NSAIDs for at least 48 hours after resolution of symptoms. 4 Avoid NSAIDs in patients with creatinine clearance (CrCL) <50 ml/min, peptic ulcers, hepatic dysfunction, congestive heart failure, and those on anticoagulation therapy. 5 In general, an NSAID with a shorter half-life is preferred (e.g., ibuprofen, diclofenac, etc). Close monitoring of creatinine, blood pressure, and electrolytes periodically is also recommended. 2 In patients with increased risk of peptic ulcers, bleeds or perforations, coadministration of gastroprotective agents such as proton pump inhibitors (omeprazoles, etc) may reduce the risk of gastrointestinal bleeding associated with NSAID use. 1-3 Head-to-head studies have shown similar benefits in gout management amongst different NSAID agents. 5,6 Some of the NSAIDs most commonly used for acute gout and their dosages include indomethacin (Indocin) 50 mg three to four times daily for three days, then 50 mg twice daily for four to seven days, naproxen (Naprosyn) 750 mg to 1000 mg daily in divided doses for three days, then 500 mg to 750 mg daily in divided doses for four to seven days, and sulindac (Clinoril) 300 mg to 400 mg daily in divided doses for seven to ten days. 7 Indomethacin should be avoided in the elderly patient due to the potential for adverse CNS effects in this age group. 4 COX-2 inhibitors, or cyclooxygenase-2 inhibitors, appear to be comparably effective to traditional NSAIDs for acute gout. 8 However, they are more costly and have been associated with increased cardiovascular risk as with other NSAIDs. 2,9,10 The same contraindications and precaution associated with traditional NSAIDs apply to the COX-2 inhibitors. Corticosteroids have established efficacy in the treatment of acute gout. 8 Some rheumatologists now recommend corticosteroids over NSAIDs as the preferred choice for treatment of acute gout. 4 Corticosteroids are especially useful in patients who cannot tolerate NSAIDs (e.g., moderate-to-severe chronic kidney disease, history of GI bleeds, etc). 8 Corticosteroids can be given orally, intravenously, intramuscularly, intraarticularly, or indirectly via adrenocorticotropic hormone (ACTH). 4 One of the safest options is intra-articular corticosteroids (e.g., methylprednisolone acetate 5 mg to 25 mg per joint, triamcinolone 10 mg per knee joint or triamcinolone 8 mg in smaller joints, or betamethasone 3 mg to 6 mg) especially if only one joint or when larger joints are involved. 1,2,9 In

(Detail-Document #261102: Page 2 of 6) patient with multiple smaller joints affected, oral, intramuscular, or intravenous corticosteroids are a shown to be too rigorous for some patients, especially the elderly, and can result in adverse more practical approach. 1 If oral treatment is events rates of 50% to 80%. 9 Alternative regimens preferred, consider a short course of daily prednisone 20 mg to 60 mg or prednisolone 35 mg or equivalent until symptoms resolve, generally such as loading the patient with 1 mg orally followed by 0.5 mg or 0.6 mg every two to six hours up to a maximum of 2.5 mg in 24 hours and within five to seven days. 9,11,12 Although 6 mg over four days or 0.5 mg to 1 mg three times corticosteroid doses are traditionally tapered over daily have been proposed. 4,7,9 The latest thinking seven to 14 days to prevent potential rebound, more recent data suggest that rebound is not an is that taking more than three 0.6 mg tablets for acute gout is not more effective and it increases issue when corticosteroids are used for short-term adverse effects. 34 The recommended dosage for (five to seven days). 9,11,13 Single-dose the brand Colcrys (U.S.) is 1.2 mg loading dose at intramuscular betamethasone 7 mg or the first sign of a gout flare followed by 0.6 mg triamcinolone acetonide 60 mg and IV one hour later. The maximum dose is 1.8 mg over methylprednisolone 125 mg have also been found a one hour period. 26 Adjust Colcrys dose and to be effective. 1 dosing frequency according to the patient s age, When steroids are used, especially for renal function, hepatic function, and usage of prolonged periods of time, patients should be interacting drugs. 26 monitored for hyperglycemia, hypertension, Colchicine can also be used prophylactically at electrolyte shifts, infections, mood, and mental problems. 2,9 Corticotropin (adrenocorticotropic hormone, ACTH) 40 units administered intramuscularly can low doses (0.6 mg orally once or twice daily) to avoid rebound flare-ups in people treated with corticosteroids or corticotropin, and to prevent recurrent attacks when urate lowering therapy is also be given to stimulate corticosteroid initiated. As with acute dosing, prophylactic production by patient s own adrenal gland. 4 In colchicine doses should be adjusted depending on addition to inducing corticosteroid production by the adrenal glands, corticotropin activates the melanocortin type 3 receptor, which interferes with the acute inflammatory response of gout. 2 the patient s renal or hepatic function, tolerability, and presence of interacting drugs. Intravenous colchicine is not recommended as it has been associated with serious toxicities, including However, corticotropin is not a preferred agent deaths. 1,8,15 Currently, there are no approved IV due to its relatively short duration of action, which increases the possibility of rebound flare-ups and treatment failure. Repeat injections are often colchicines available in the U.S. or Canada and the FDA has ordered companies to stop making unapproved IV colchicines. 15 required to eliminate symptoms of acute gout attack. 9,14 To be effective, corticotropin requires Management of Chronic Gout an unsuppressed adrenal axis and should not be The goal of long-term gout management is to administered to patients who have recently lower serum uric acid levels to approximately received systemic steroids. 14 6 mg/dl (360 umol/l) or less. 4,6 In some cases, Colchicine has been used for the treatment of <5 mg/dl (300 umol/l) is needed for resolution gout for centuries. However, it has fallen out of of tophi. 2 Urate-lowering therapy is the main favor as a drug of choice for acute gout due to its focus of chronic gout management. The decision narrow therapeutic index and poor tolerability. 4,8 to begin urate-lowering therapy depends on the About 80% of patients cannot tolerate the frequent baseline serum uric acid levels, an individual s GI side effects (e.g., nausea, vomiting, diarrhea). 4 risk for recurrent gout attacks, and/or damage by It is a poor choice for patients with renal impairment, hepatic impairment, or arrhythmias, tophi (deposits of monosodium urate stones). 1 Uric acid levels >9 mg/dl (540 umol/l) pose a since these conditions can enhance the risk of higher risk for recurrent gouty arthritis. 4 In colchicine s toxicity. 1 general, urate-lowering therapy should be In the past, colchicine was generally dosed at 0.6 mg taken orally every hour until relief or sideeffects considered in uncomplicated gout if a second attack or further attacks of gout occur within one occur or until a maximum dosage of 6 mg is reached. However, this regimen has been year. 1 Therapy should be considered in patients

with visible gouty tophi, renal insufficiency, and those who need to continue to take diuretics. 1 Urate-lowering therapy should not be initiated during an acute attack due to risk of rebound or flares of acute gout attack. It is recommended to initiate urate-lowering therapy within one to two weeks after the acute attack has subsided. 1 Xanthine oxidase inhibitor, such as allopurinol (Zyloprim, Alloprin [Canada]), is the agent of choice to lower serum uric acid. Allopurinol blocks xanthine oxidase and thereby reduces the generation of uric acid. Allopurinol is effective in both underexcreters (those with 24 hour urine uric acid <800 mg on a regular diet or 600 mg in 24 hours on a purine-restricted diet) and overproducers (those with 24 hour urine uric acid >800 mg). 2,14 Allopurinol is generally dosed from 100 mg to 800 mg/day with 300 mg/day being the most commonly prescribed dose. 1,8,9 (Doses greater than 300 mg/day are given in divided doses, two or three times daily.) 28 In patients with normal renal function, the dose depends on disease severity. The minimum effective dose is 100 to 200 mg daily. The average daily dose is 200 to 300 mg for mild gout, 400 to 600 mg for moderate gout, and for severe gout, 700 to 800 mg. 28,29 Experts recommend starting with 100 mg per day, then increasing by 100 mg per day once every one to four weeks until target serum uric acid is achieved. For patients with renal insufficiency, the starting dose is 50 to 100 mg per day. Serum uric acid should be measured monthly and the dosage increased monthly until the target serum uric acid level is achieved. 9 Per current product labeling, patients with CrCl 10 to 20 ml/min should receive no more than 200 mg daily. Patients with CrCl less than 10 ml/min should not receive >100 mg daily. Patients with CrCl <3 ml/min should lengthen the interval between doses. 28,29 Experts suggest that allopurinol is generally under-dosed in clinical practice with 300 mg/day (Detail-Document #261102: Page 3 of 6) Side effects of allopurinol include rash, GI disturbances, and headache. Rarely, potentially fatal hypersensitivity reactions can occur, more commonly in patients with renal insufficiency and those who are taking a diuretic. 4 To prevent an acute attack as a result of starting allopurinol, prophylactic colchicine 0.6 mg once or twice daily or a low-dose NSAID (e.g., indomethacin 25 mg twice daily or naproxen 250 mg twice daily) can be used if there are no limitations. 1,9 Colchicine dosage should be adjusted depending on patient renal and hepatic function, tolerability, and presence of interacting drugs. Prophylactic treatment is best started two to three weeks prior to starting allopurinol or other uric acid-lowering agent and continued for up to six months. 2 The British guidelines recommend limiting the duration of NSAID use to six weeks. 1 A general approach is to continue prophylactic treatment until serum uric acid is within normal range. Prophylactic treatment is not recommended unless the patient is taking a uric acid lowering agent. Corticosteroids are not ideal for gout exacerbation related to allopurinol use since the potential for adverse effects increases with prolonged use of corticosteroids. Allopurinol should not be discontinued during treatment of acute attacks. 9 Febuxostat (Uloric), a selective xanthine oxidase inhibitor, was approved in the U.S. in 2009 and in Canada in 2010. Febuxostat lowers serum uric acid levels by inhibiting both the oxidized and reduced forms of xanthine oxidase. Febuxostat does not have a purine-like core structure, which has been implicated in some of the sensitivity reactions seen with allopurinol. 8,19 The recommended dosage of febuxostat is 40 mg to 80 mg daily in the U.S. and 80 mg daily in Canada. 20,30 No dosage adjustment is needed for patients with mild to moderate renal or hepatic impairment. In comparative trials, the efficacy of febuxostat 40 mg daily appears to be comparable to allopurinol 300 mg daily, and febuxostat 80 mg daily appears to be more effective than allopurinol 300 mg daily in reducing uric acid levels to goal <6 mg/dl (360 umol/l). It should being the most commonly prescribed dose. 1,8 The reasons for underutilization of allopurinol are concerns of its adverse effects (GI intolerance, rash, rare but frequently fatal hypersensitivity be noted that these studies only used allopurinol syndrome), conservative renal dosage adjustment, doses up to 300 mg daily. 8,19 Although febuxostat and inadequate published randomized controlled is a more selective xanthine oxidase inhibitor than trials of efficacy and safety of allopurinol over allopurinol, it is unclear if this will offer more 300 mg/day. 8,16 The conservative allopurinol effective control of gout flares. Febuxostat is renal adjustment has been disputed. 17,18 significantly more costly than allopurinol.

Consider febuxostat in patients with allopurinol drug hypersensitivity, intolerance, or treatment failure. 8 Uricosurics, such as probenecid (Benemid, Benuryl [Canada] and sulfinpyrazone (Aposulfinpyrazone [Canada only]), increase uric acid excretion. Uricosuric agents should only be used in younger patients (<60 years old) that are underexcreters of uric acid, who do not have reduced renal function (CrCl >60 ml/min) or history of kidney stones, and who do not require aspirin or diuretic therapy. 2,8 Low-dose aspirin (75 mg/day to 150 mg/day) does not appear to have significant effect on serum uric acid level, while aspirin in higher doses (600 mg/day to 2400 mg/day) can reduce the effectiveness of uricosuric agents. High-dose aspirin should be avoided. 1 Side effects include GI disturbances, rash, and kidney stone formation. Per U.S. product labeling, the usual initial dose of probenecid is 250 mg twice daily for one week followed by 500 mg twice daily thereafter. 14,31 Some patients may require further titration up to a maximum of 2 grams daily given in divided doses, two or three times a day. 31 Per Canadian product labelling, the initial dose is 250 mg twice daily for one week, then increase to 500 mg twice daily. If symptoms persist, in nongeriatric patients dose can be increased every four weeks in 500 mg increments. The maintenance dose is 1000 mg to 3000 mg daily in divided doses (two or three times per day 9 ). 33 The usual sulfinpyrazone (Canada only) dose is 200 mg to 400 mg per day (given in divided doses, two to three times daily 9 ). 32 The dosage can be increased to 800 mg per day if necessary or lowered to as low as 200 mg per day (Detail-Document #261102: Page 4 of 6) Pegloticase should only be administered under the supervision of a healthcare professional due to the risk of infusion reactions and anaphylaxis. Patients should be premedicated with antihistamines and corticosteroids prior to infusion and should be closely monitored. Since the risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response, patients serum uric acid levels should be monitored prior to infusions and discontinuation of treatment should be considered if uric acid level increases to above 6 mg/dl (360 umol/l), particularly when two consecutive levels above 6 mg/dl (360 umol/l) are observed. 21 In the first few months of therapy, up to 80% of patients treated with pegloticase experience gout flare, but it tapers off with continued therapy in responders. 8 Discontinuation of pegloticase is not necessary if gout flare occurs; however, gout flare prophylaxis with NSAIDs or colchicine is recommended for at least the first six months of treatment unless there are contraindications. Side effects of pegloticase include gout flares, infusion reaction, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting. Use with caution in patients with congestive heart failure as heart failure exacerbations have been reported in clinical trials. 21 Pegloticase is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis and methemoglobinemia. Screening patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) is recommended prior to initiation of pegloticase therapy. Reserve pegloticase for patients who are not responsive to appropriately dosed oral uratelowering therapies. Although uricase oxidase (e.g., rasburicase [Elitek, Fasturtec, Canada]) has been used to treat chemotherapy-induced hyperuricemia for years, the safety and efficacy of pegloticase in the treatment of chemotherapyinduced hyperuricemia is unknown. Expect Krystexxa to cost more than $20,000/year, compared to under $100/year (U.S.) for allopurinol and under $2000/year (U.S.) for Uloric. if blood urate level is controlled. 32 Both drugs should be titrated to a serum uric acid level of 6 mg/dl (360 umol/l) or less. 9 Krystexxa (pegloticase), a PEGylated uric acid specific enzyme (urate oxidase), is the latest FDA approved agent for the management of refractory gout. It works by catalyzing the oxidation of uric acid to allantoin, which is an inert and water soluble purine metabolite that can be easily excreted renally. In clinical trials, pegloticase 8 mg administered intravenously every two weeks was shown to lower serum uric acid level and significantly improve or reverse the course of severe, crippling, and debilitating refractory Emerging Therapies gout. 21 After six months of therapy, 45% of Preliminary data on biologic therapies such as patients achieved complete resolution of tophi. anakinra (Kineret) and rilonacept (Arcalyst, U.S.

only), both anti IL-1 agents; etanercept (Enbrel) and infliximab (Remicade), both TNF-alpha inhibitors; and canakinumab (Ilaris) (anti IL-1 beta agent) have shown them to be useful in the treatment of acute refractory gout. 22-24 Use of these emerging therapies may be considered in patients with refractory gout. However, referral to a rheumatologist is recommended in these cases. Several investigational agents for gout management being studied include apremilast (phosphodiesterase 4 and TNF-alpha inhibitor), uricase-peg 20 (urate oxidase), RDEA594 (uricosuric), and BCX-4208 (purine nucleoside phosphorylase inhibitor). 22 Other Preventive Measures In patients with recurrent gout attacks, offending drugs (e.g., thiazide diuretics, niacin, levodopa, cyclosporine, ethambutol, pyrazinamide, aspirin, etc) should be removed if applicable. 9,25 In addition, patients should be counseled about lifestyle changes that may help reduce the incidence of gout attack. 1,6,9 Limiting alcohol intake is recommended. Chronic alcohol intake and binge drinking should be avoided. Beer contains high purine content and has the highest risk for inducing gout attack. Moderate wine drinking does not increase the risk of gout. However, the quantity of alcohol, regardless of type consumed, strongly correlates with gout. 1,9 Complete dietary purine restriction is rarely necessary, and it s been shown that a diet totally restricted in purines lowers the mean serum uric acid level by only about 1 mg/dl. 1 However, limiting high purine foods (e.g., red meat) and limiting high protein content in diet is recommended. 1 Liver, kidney, shellfish, and yeast extracts should be avoided. 1 In obese patients, a modified diet to help achieve ideal body weight should be considered. However, patients should be warned to stay away from high-protein, lowcarbohydrate diets (e.g., Atkins diet, etc). Encourage patients to drink lots of water, especially those with history of kidney stones. 1 Conclusion There are a number of medications (e.g., NSAIDs, colchicine, corticosteroids) used for the management of acute gout attacks. When selecting a drug, a patient s comorbid conditions (Detail-Document #261102: Page 5 of 6) and chronic medications should be taken into consideration. To prevent future gout attacks, allopurinol or uricosuric agents can be used to lower serum uric acid level. In patients who are intolerant or have failed allopurinol and uricosuric agents, febuxostat can be considered [Evidence level C, consensus]. 6,27 In refractory gout that is resistant to conventional treatments, pegloticase can be considered. Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and Internet links in this article were current as of the date of publication. Levels of Evidence In accordance with the trend towards Evidence-Based Medicine, we are citing the LEVEL OF EVIDENCE for the statements we publish. Level A B C D Definition High-quality randomized controlled trial (RCT) High-quality meta-analysis (quantitative systematic review) Nonrandomized clinical trial Nonquantitative systematic review Lower quality RCT Clinical cohort study Case-control study Historical control Epidemiologic study Consensus Expert opinion Anecdotal evidence In vitro or animal study Adapted from Siwek J, et al. How to write an evidence-based clinical review article. Am Fam Physician 2002;65:251-8. Project Leader in preparation of this Detail- Document: Wan-Chih Tom, Pharm.D. References 1. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for management of gout. Rheumatology (Oxford) 2007;46:1372-4. 2. Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics 2008;63:13-8,20.

(Detail-Document #261102: Page 6 of 6) 3. Wilson JF. In the Clinic. Gout. Ann Intern Med 2010;152:ITC21. 4. Miller AV, Ranatunga SKM, Francis ML. Gout. emedicine. September 15, 2010. http://emedicine.medscape.com/article/329958- overview. (Accessed October 12, 2010). 5. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford) 2010;49:5-14. 6. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Reports of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. 7. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8 Suppl 1:S3. 8. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-8. 9. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging 2007;24:21-36. 10. Cardiovascular risks of NSAIDs and COX-2 inhibitors. Pharmacist's Letter/Prescriber's Letter 2006;22(10):221003. 11. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60. 12. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7. 13. Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008;(2):CD005521. 14. Gout: Review of treatment options. Pharmacist's Letter/Prescriber's Letter 2003;19(10):191007. 15. Anon. Questions and answers about FDA s enforcement action against unapproved injectable colchicine products. FDA. May 15, 2009. http://www.fda.gov/drugs/guidancecompliancere gulatoryinformation/enforcementactivitiesbyfda/s electedenforcementactionsonunapproveddrugs/uc m119642.htm. (Accessed October 13, 2010). 16. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008;20:167-72. 17. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50. 18. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3. 19. New drug: Uloric (febuxostat). Pharmacist's Letter/Prescriber's Letter 2009;25(4):250413. 20. Product monograph for Uloric. Takeda Canada, Inc. Mississauga, Ontario L5N 2V8. September 21, 2010. 21. Product information for Krystexxa. Savient Pharmaceuticals, Inc. East Brunswick, NJ 08816. September 2010. 22. Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010;22:188-93. 23. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2010;DOI:10.1016/50140-6736(10)60665-4. 24. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008;20:198-202. 25. Richette P, Bardin T. Gout. Lancet 2010;375:318-28. 26. Product information of Colcrys. Mutual Pharmaceutical Company, Inc. Philadelphia, PA 19124. May 2010. 27. Jansen TL, Richette P, Perez-Ruiz F, et al. International position paper on febuxostat. Clin Rheumatol 2010;29:835-40. 28. Product monograph for Zyloprim. AA Pharma Inc. Vaughn, ON L4K 4N7. September 2010. 29. Product information for Zyloprim. Prometheus Labs, Inc. San Diego, CA 92121. October 2003. 30. Product information for Uloric. Takeda Pharmaceuticals America, Inc. Deerfield, IL 60015. February 2009. 31. Product information for probenecid. Watson Pharma, Inc. Corona, CA 92880. June 2009. 32. Product monograph for sulfinpyrazone. AA Pharma, Inc. Toronto, ON M5X 1C7. May 2010. 33. Product monograph for Benuryl. Valeant Canada Limited. Montreal, QC H4R 2P9. September 2004. 34. New safety information for colchicine and the approval of Colcrys. Pharmacist s Letter/Prescriber s Letter 2009;25(9):250902. Cite this Detail-Document as follows: Management of gout. Pharmacist s Letter/Prescriber s Letter 2010;26(11):261102. Evidence and Advice You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249 Subscribers to Pharmacist s Letter and Prescriber s Letter can get Detail-Documents, like this one, on any topic covered in any issue by going to www.pharmacistsletter.com or www.prescribersletter.com